Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3% – What’s Next?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s share price traded down 5.3% during mid-day trading on Friday . The stock traded as low as $9.55 and last traded at $9.56. 41,906 shares changed hands during trading, a decline of 93% from the average session volume of 612,849 shares. The stock had previously closed at $10.09.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ATXS shares. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. TD Cowen began coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Finally, Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Price Performance

The stock’s 50 day simple moving average is $11.40 and its two-hundred day simple moving average is $10.62. The stock has a market capitalization of $528.66 million, a PE ratio of -4.48 and a beta of 0.71.

Institutional Trading of Astria Therapeutics

Several hedge funds have recently made changes to their positions in the company. Quest Partners LLC grew its stake in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares during the last quarter. PDT Partners LLC bought a new position in Astria Therapeutics during the third quarter worth about $140,000. SG Americas Securities LLC purchased a new position in shares of Astria Therapeutics in the third quarter worth about $155,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Astria Therapeutics in the second quarter valued at approximately $171,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.